



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/631,029
				Filing Date	July 29, 2003
				First Named Inventor	Rajinder Singh
				Art Unit	Unknown
				Examiner Name	Unknown
Sheet	3	of	7	Attorney Docket Number	28575/US/US

FOREIGN PATENT DOCUMENTS

Examiner Initial	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
JL		WO	03/018021	3/6/2003	Amgen Inc.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/016306	2/27/2002	Janssen Pharmaceutica N.V.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/002544	1/9/2003 2/03	Bristol-Myers Squibb Company		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/000186	1/3/2003	Ariad Pharmaceuticals Inc.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	02/102313	12/27/2002	Bristol-Myers Squibb Company		<input type="checkbox"/>	<input type="checkbox"/>
		WO	02/066481	8/29/2002	Astrazeneca AB		<input type="checkbox"/>	<input type="checkbox"/>
		WO	02/066480	8/29/2002	Astrazeneca AB		<input type="checkbox"/>	<input type="checkbox"/>
		WO	02/066461	8/28/2002	Vertex Pharmaceuticals, Inc.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	02/064096	8/22/2002	Tularik Inc.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	02/062789	8/15/2002	Vertex Pharmaceuticals, Inc.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	02/059112	8/1/2002	Vertex Pharmaceuticals, Inc.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	02/059110	8/1/2002	Glaxo Group Limited		<input type="checkbox"/>	<input type="checkbox"/>
		WO	02/50066	6/27/2002	Vertex Pharmaceuticals, Inc.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	02/45652	6/13/2002	Merck & Co. Inc.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	02/22601	3/21/1002	Vertex Pharmaceuticals, Inc.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	02/04429	1/17/2002	Astrazeneco AB		<input type="checkbox"/>	<input type="checkbox"/>
		WO	01/85700	11/15/2001	Janssen Pharmaceutica N.V.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	01/85699	11/15/2001	Janssen Pharmaceutica N.V.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	01/72744	10/4/2001	Schering Aktiengesellschaft		<input type="checkbox"/>	<input type="checkbox"/>
		WO	01/64656	9/7/2001	Astrazeneca AB		<input type="checkbox"/>	<input type="checkbox"/>
	WO	01/64654	9/7/2001	Astrazeneca AB		<input type="checkbox"/>	<input type="checkbox"/>	
	WO	01/64655	9/7/2001	Astrazeneca UK Limited		<input type="checkbox"/>	<input type="checkbox"/>	
JL		WO	00/63182 10/00	4/20/1999	Bayer Aktiengesellschaft		<input type="checkbox"/>	<input checked="" type="checkbox"/>


EXAMINER SIGNATURE

Wes

DATE CONSIDERED

8-18-05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/631,029
				Filing Date	July 29, 2003
				First Name of Inventor	Rajinder Singh
				Art Unit	Unknown
				Examiner Name	Unknown
Sheet	2	of	7	Attorney Docket Number	28575/US/US

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
U		US- 5,420,129	5/30/1995	Breu	
		US- 5,223,505	6/29/1993	Hargreaves	
		US- 5,179,204	1/12/1993	Effland et al.	
		US- 5,147,876	9/15/1992	Mizuchi et al.	
		US- 4,983,608	1/8/1991	Effland et al.	
U		US- 3,159,547	12/1/1964	Hollis et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code:	Number - Kind Code (if known)				YES	NO
U		WO	03/078404	9/25/2003	Novartis Pharma GmbH		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/074515	9/12/2003	Smithkline Beecham Corporation		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/066601 8/03	2/8/2002	Smithkline Beecham Corporation		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/062225	7/31/2003	Bayer Corporation		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/063794	8/7/2003	Rigel Pharmaceuticals Inc.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/048133	6/12/2003	Astrazeneca AB		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/040141	5/15/2003	Bayer Corporation		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/032997	4/24/2003	Boehringer Ingelheim Pharma KG		<input type="checkbox"/>	<input checked="" type="checkbox"/>
		WO	03/032994	4/24/2003	Boehringer Ingelheim Pharma KG		<input type="checkbox"/>	<input checked="" type="checkbox"/>
		WO	03/030909	4/17/2003	Bayer Corporation		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/026666	4/3/2003	Bayer Corporation		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/026665	4/3/2003	Bayer Corporation		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/026664	4/3/2003	Bayer Corporation		<input type="checkbox"/>	<input type="checkbox"/>
U		WO	03/018022	3/6/2003	Amgen Inc.		<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE


U

DATE CONSIDERED

8-18-05-

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO (Modified)		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/631029
		Filing Date	July 29, 2003
		First Named Inventor	Rajinder SINGH
		Art Unit	1614
		Examiner Name	K. WEDDINGTON
		Attorney Docket Number	375462-012US (355218)
Sheet	1	of	1



U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number-Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
<i>PRP</i>	A1	10/355,543 (US 20040029902)	02-12-2004	<i>Singh, et al.</i>	<i>Singh, et al.</i>
	A2	10/858,343 (US 20050038243)	02-17-2005	<i>Singh, et al.</i>	
	A3	11/299,207	NOT AVAILABLE		
	A4	10/911,684 (US 20050209230)	09-22-2005	<i>Singh, et al.</i>	
	A5	11/148,746 (US 20060035916)	02-16-2006	<i>Singh, et al.</i>	
	A6	11/149,105 (US 20060025410)	02-06-2006	<i>Singh, et al.</i>	
	A7	11/149,418	NOT AVAILABLE		
	A8	10/903,263 (US 20050234049)	10-20-2005	<i>Singh, et al.</i>	
	A9	10/903,870 (US 20050209224)	09-22-2005	<i>Singh, et al.</i>	
	A10	11/016,403 (US 20050192301)	09-01-2005		
	A11	10/913,270 (US 20050113398)	05-26-2005	<i>Argade, et al.</i>	
	A12	11/286,238	NOT AVAILABLE		
	A13	11/133,419 (US 20060035891)	02-16-06	<i>Li, et al.</i>	
	A14	11/216,532	NOT AVAILABLE		
	A15	11/280,066	NOT AVAILABLE		
	A16				
	A17				
	A18				

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document Country Code* Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	B1				

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and country where published.		
	C1			
	C2			

Examiner Signature	<i>[Signature]</i>	Date Considered	9/26/06	12419946.1.BUSINESS
--------------------	--------------------	-----------------	---------	---------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2